Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

08 mai 2025 05h01 HE | Source: Research and Markets

Anti-CD279 (PD-1) Antibody Pipeline Insight Report 2025 Featuring Analysis of 40+ Companies & Drugs Including IBI308 (Innovent Biologics) and Tislelizumab (BeiGene)

Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The "Anti-CD279 (PD-1) Antibody - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides...
11 avr. 2024 09h15 HE | Source: Research and Markets

Anti-CD279 (PD-1) Antibody Drug Pipeline Research Report 2024: Insights on 40+ Companies Featuring GlaxoSmithKline, Innovent Biologics, BeiGene, and Shanghai Junshi Biosciences

Dublin, April 11, 2024 (GLOBE NEWSWIRE) -- The "Anti-CD279 (PD-1) Antibody - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This "Anti-CD279 (PD-1)...